Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A second Phase 3 Trial of Avasopasem-manganese

Trial Profile

A second Phase 3 Trial of Avasopasem-manganese

Status: Suspended
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avasopasem manganese (Primary)
  • Indications Stomatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Galera Therapeutics
  • Most Recent Events

    • 14 Aug 2024 According to a Galera Therapeutics media release, the Company ceased all clinical trial activity and suspended the clinical development of its product candidates as it explored potential strategic alternatives.
    • 14 Aug 2024 Status changed from planning to suspended, according to a Galera Therapeutics media release.
    • 05 Apr 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top